Email Facebook Twitter

RNS EXCLUSIVE: Cabot praise 3D seismic mapping after successful winter programme

Alliance News

Abzena Extends Agreements With Research Institutes For HIV Vaccines

Mon, 12th Jan 2015 09:59

LONDON (Alliance News) - Life sciences company Abzena PLC on Monday said its Antitope Ltd subsidiary has extended its collaboration with three research institutes for work on developing HIV vaccines.

Antitope is working with the French National Institute of Health and Medical Research INSERM, the National Health Agency for Research on AIDS and Hepatitis ANRS, and the Baylor Institute for Immunology Research.

INSERM-ANRS and Baylor have developed approaches to HIV vaccines targeting HIV antigens to dendritic cells using monoclonal antibodies fused to HIV antigens. Antitope is to produce cell lines for the manufacturing of two anti-CD40-HIV fusion proteins which the research institutes are developing as potential therapeutic and prophylactic vaccines to treat HIV.

The cell lines are to be manufactured using Antitope's Composite CHO technology.

"This project further extends our relationship with Baylor in developing a range of therapeutic vaccines for the treatment of diseases such as HIV," said Abzena Chief Scientific Officer Matthew Baker.

Abzena shares were untraded on Monday, having last traded at 81.60 pence.

By Sam Unsted;; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.

Alliance News

Related Shares:

Back to Alliance News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.